Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|March 12, 2010
Rheumatoid arthritis treatment suspended
Author(s)Stephanie Sutton
Following a number of serious adverse events, including infections and fatalities, Roche and Biogen Idec have suspended the late-stage development of Ocrelizumab for the treatment of rheumatoid arthritis (RA).
Advertisement
Following a number of serious adverse events, including infections and fatalities, Roche and Biogen Idec have suspended the late-stage development of Ocrelizumab for the treatment of rheumatoid arthritis (RA). The decision follows a recommendation made by the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board based on studies in RA and lupus.
"The DSMB concluded that the safety risk outweighs the benefits observed in these specific patient populations at this time," explained a
The press statement also adds that a detailed analysis of all data will be conducted to "further inform the future of the Ocrelizumab RA clinical programme".
This is the latest in a number of setbacks for the treatment. According to the press statement, the companies have also previously halted an Ocrelizumab study in lupus nephritis patients because of infection signals and placed a study involving MTX-naive RA patients on clinical hold following an assessment of benefit to risk in this specific RA population.
However, the drug is still being evaluated for relapsing remitting multiple sclerosis and is currently undergoing a Phase II study.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement